๐ฌDeep Research
DNA โ Ginkgo Bioworks ยท catalysts, narrative & risks
Ginkgo Bioworks (NYSE: DNA) โ As of October 25, 2026
Below is a point-in-time research summary. It is informational only, not investment advice.
Company snapshot (Oct 23, 2026)
- NYSE-listed biotech developing a cell-engineering platform [16], [18].
- Price ~$9.99, market cap ~$672.7M, ~67.34M shares outstanding, beta 1.79 [20].
- 52-week range $5.37โ$18.22 [20]. Over the trailing 12 months DNA fell roughly 26% while the S&P 500 rose ~12% [18].
- Fundamentals are weak relative to peers: trailing revenue ~$132.4M (โ37%) and net loss ~$290.8M, EPS โ$4.96 [20]. For context, 2025 revenue was $170.2M, down
25% [20]. (Note [1] cites "$170M revenue," which appears to reflect the 2025 annual figure rather than the trailing-twelve-month number.)
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ